Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 8.01 (Other Events). New ATM facility authorizes up to $50 million in additional common-stock sales through Jefferies.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- New ATM facility authorizes up to $50 million in additional common-stock sales through Jefferies
- Prior 2025 ATM fully utilized, with approximately $50 million sold as of November 12, 2026
- Potential equity issuance creates shareholder dilution and supplies additional capital for operations
- Jefferies receives a 3.0% commission on gross proceeds from shares sold
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.